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INTRODUCTION

Globally over 100 million people are affected by heart
valve (HV) related diseases and 300,000 HV
replacements are required annually (Kheradvar et al.,
2015). While HV replacement is a common procedure for
adult patients, the inability of mechanical or bioprosthetic
HVs to grow makes replacement surgery the final choice
for paediatric patients, as multiple revision surgeries are
often required. Tissue engineered heart valves (TEHVs)
are the new paradigm and promise integration with the
native vasculature, thereby facilitating growth and
remodelling in vivo. This could eliminate paediatric
patients’ need for revision surgeries.
The TE approach we are interested in combines
autologous
cells
with
a
fibrin-collagenglycosaminoglycan scaffold (Brougham et al., 2017,
2015), and this construct is subsequently conditioned
using a bioreactor. The bioreactor simulates the
mechanical action of the heart, encouraging the
directional proliferation of cells and the development of
a biomimetic extracellular matrix. While many HV
bioreactors have been developed, the ideal set up and
conditioning regime to create a fully functional TEHV
remains unknown. Therefore, the long term goal of this
project is create a TEHV from the previously developed
scaffolds (Brougham et al., 2017, 2015) suitable for in
vivo trials. The initial project aim was to design a
bioreactor that was capable of conditioning HVs using a
range of parameters.

DESIGN REQUIREMENTS

The design requirements of the bioreactor included the
ability to mimic both an adult and a neonate heart (heart
rates 30 to 200 bpm, flow through the HV of 25 to 100
ml/beat and a pressure drop of 13 to 25 mmHg across the
valve). The bioreactor must be fabricated from noncytotoxic materials and be easy to sterilise (using
ethylene oxide and/or autoclaving). It must facilitate gas
exchange and media exchange while being housed inside
an incubator and must remain sterile throughout the
culture period. The delivery of the HV into the bioreactor
must be accomplished using aseptic technique, the valve
must be suitably fixed in place and be visible throughout
the culture period. These design requirements were met
in the proposed concept (Figure 1).

DESIGN CONCEPT

The bioreactor houses the HV in a central position
between the pulmonary (3) and ventricular (2) chambers.
Media is pumped through the valve by the displacement
of a silicone membrane (f) and secured in a stainless steel

base (1). This is achieved using a magnetic actuator,
controlled using Labview. Silicone tubing will allow
displaced media to circulate between polypropylene
connectors (a) and (b), while a peristaltic pump will
pump media between connectors (c) and (d). The main
body (2, 3) and lid (4) of the bioreactor will be fabricated
from PMMA with the design of the lid allowing clear
observation of the HV leaflets. A compliance chamber
will be attached to connector (e) to simulate arterial
expansion and a syringe filter to promote gas exchange.

Figure 1 Bioreactor design showing a heart valve in red.
Bioreactor contains a base (1), ventricular chamber (2),
pulmonary chamber (3), lid (4), heart valve support (5),
connectors (a, b, c, d, and e) and silicone membrane (f).

DISCUSSION

This bioreactor design is loosely based on the conceptual
design proposed by Hoerstrup et al. (2000), and uses
elements from the bioreactor designed by Moreira et al.
(2014). However, unlike those designs, here the
ventricular chamber acts as a nozzle to direct the flow
towards the HV. Operating parameters will be validated
using a mechanical HV and measuring the pressure drop
across the valve using pressure transducers. A flow
sensor will measure the shear flow through the HV.
Additionally, cytotoxicity tests are required to validate
the choice of materials while sterility tests are required to
validate its operating conditions. In time, this bioreactor
will be employed to condition TEHVs using a variety of
conditioning regimes.
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